Week 96 efficacy and safety data: Elvitegravir/cobicistat/emtricitabine/tenofovir DF (Quad) compared to atazanavir boosted by ritonavir plus emtricitabine/tenofovir DF in treatment-naive HIV-1-infected patients

被引：0
|
作者：
Orkin, C. [1 ]
Rockstroh, J. [2 ]
DeJesus, E. [3 ]
Henry, K. [4 ]
Molina, J. [5 ]
Gathe, J. [6 ]
Wei, X. [7 ]
Fordyce, M. [7 ]
Rhee, M. [7 ]
Smith, A. [8 ]
Szwarcberg, J. [7 ]
机构：
[1] St Bartholomews Hosp, London, England
[2] Univ Bonn, Bonn, Germany
[3] Orlando Immunol Ctr, Orlando, FL USA
[4] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA
[5] St Louis Hosp, Paris, France
[6] Therapeut Concepts PA, Houston, TX USA
[7] Gilead Sci Inc, Foster City, CA 94404 USA
[8] Gilead Sci Inc, Cambridge, England
来源：
HIV MEDICINE | 2013年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
引用
收藏
页码：56 / 56
页数：1
相关论文
共 50 条
  • [31] Overdose of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in an HIV-1-infected subject with attempted suicide
    Alvarez, Hortensia
    Marino, Ana
    Valcarce, Nieves
    Garcia-Gonzalez, Jesus
    Diaz-Cambre, Helena
    Llibre, Josep M.
    [J]. INFECTION, 2019, 47 (01) : 115 - 119
  • [32] A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naive patients
    DeJesus, E.
    Mills, A.
    Bhatti, L.
    Conner, C.
    Storfer, S.
    [J]. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2011, 65 (12) : 1240 - 1249
  • [33] Switching to the single-tablet regimen of elvitegravir, cobicistat, emtricitabine, and tenofovir DF from non-nucleoside reverse transcriptase inhibitor plus coformulated emtricitabine and tenofovir DF regimens: Week 96 results of STRATEGY-NNRTI
    Pozniak, Anton
    Flamm, Jason
    Antinori, Andrea
    Bloch, Mark
    Ward, Douglas
    Berenguer, Juan
    Cote, Pierre
    Andreatta, Kristen
    Garner, William
    Szwarcberg, Javier
    Nguyen-Cleary, Thai
    McColl, Damian J.
    Piontkowsky, David
    [J]. HIV CLINICAL TRIALS, 2017, 18 (04): : 141 - 148
  • [34] Week 96 results of a phase 3 trial of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naive HIV-1 patients
    Orkin, Chloe
    Eron, Joseph J.
    Rockstroh, Juergen
    Podzamczer, Daniel
    Esser, Stefan
    Vandekerckhove, Linos
    Van Landuyt, Erika
    Lathouwers, Erkki
    Hufkens, Veerle
    Jezorwski, John
    Opsomer, Magda
    [J]. AIDS, 2020, 34 (05) : 707 - 718
  • [35] Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naive HIV-1-infected patients
    Vrouenraets, S. M. E.
    Wit, F. W. N. M.
    Garcia, E. Fernandez
    Moyle, G. J.
    Jackson, A. G.
    Allavena, C.
    Raffi, F.
    Jayaweera, D. T.
    Mauss, S.
    Katlama, C.
    Fisher, M.
    Slama, L.
    Hardy, W. D.
    DeJesus, E.
    van Eeden, A.
    Reiss, P.
    [J]. HIV MEDICINE, 2011, 12 (10) : 620 - 631
  • [36] Hepatic safety profile of elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV/HCV co-infected subjects in the STRATEGY switch trials
    Rashbaum, B.
    Lucasti, C.
    Mounzer, K.
    Melbourne, K.
    Kwon, P.
    Piontkowsky, D.
    [J]. ANTIVIRAL THERAPY, 2014, 19 : A44 - A45
  • [37] Efficacy and Safety of elvitegravir/cobicistat/emtricitabine/tenofovir DF from an integrated analysis of Phase 2 and 3 clinical trials
    Fisher, M.
    Ward, D.
    Crowfoot, G.
    Shamblaw, D.
    Bellos, N.
    Chen, S.
    Rhee, M.
    Aizen, K.
    Szwarcberg, J.
    [J]. HIV MEDICINE, 2013, 14 : 55 - 55
  • [38] THE 48-WEEK EFFICACY AND SAFETY OF SWITCHING TO FIXED-DOSE EFAVIRENZ/EMTRICITABINE/TENOFOVIR DF IN HIV-1-INFECTED PATIENTS RECEIVING HAART
    Carlevari, M.
    DeJesus, E.
    Pozniak, A.
    Gallant, J.
    Arribas, J.
    Lazzarin, A.
    Zhou, Y.
    Cheng, A.
    Warren, D.
    Enejosa, J.
    [J]. INFECTION, 2009, 37 : 62 - 62
  • [39] Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide as Maintenance Treatment in HIV/HBV-Coinfected Patients
    Huang, Yu-Shan
    Cheng, Chien-Yu
    Liou, Bo-Huang
    Lu, Po-Liang
    Cheng, Shu-Hsing
    Lee, Yuan-Ti
    Liu, Chun-Eng
    Sun, Hsin-Yun
    Yang, Chia-Jui
    Tang, Hung-Jen
    Lin, Shih-Ping
    Ho, Mao-Wang
    Huang, Sung-Hsi
    Tsai, Hung-Chin
    Lee, Chen-Hsiang
    Hung, Chien-Ching
    [J]. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2021, 86 (04) : 473 - 481
  • [40] The pharmacokinetics, pharmacodynamics and clinical efficacy of elvitegravir plus cobicistat plus emtricitabine plus tenofovir combination therapy for the treatment of HIV
    Raffe, Sonia
    Fisher, Martin
    [J]. EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (03) : 427 - 435
12345